NASDAQ:NCEL NLS Pharmaceutics Q2 2026 Earnings Results & Report $2.68 -0.07 (-2.55%) As of 02:53 PM Eastern NLS Pharmaceutics reported Q2 2026 earnings on September 18, 2026. The company reported EPS of -$0.48. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2026Report DateSeptember 18, 2026TimeBefore Market Opens NLS Pharmaceutics EPS ResultsActual EPS-$0.48Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ANLS Pharmaceutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesEarnings HistoryCompany Profile NLS Pharmaceutics Q2 2026 Earnings FAQ Did NLS Pharmaceutics beat earnings estimates for Q2 2026? NLS Pharmaceutics (NASDAQ:NCEL) reported earnings of -$0.48 per share for Q2 2026. The report was announced on Friday, September 18, 2026. NLS Pharmaceutics Earnings HeadlinesNewcelX Announces Pricing of $1.55 Million Equity Financing at 20% Premium Pricing to MarketNovember 9, 2026 | globenewswire.comNewcelX Enters into Binding Term Sheet to Divest Legacy Mazindol Portfolio (CVR), Providing for Upfront Cash, Equity Ownership and Up to $55 Million in Potential Milestone PaymentsNovember 4, 2026 | globenewswire.comTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Trading's Thomas Wood calls it one of the firm's most powerful proprietary trading indicators, and says the company has never run a deal like this before. There are no strings attached, just a steep Black Friday discount on a tool built for traders.November 17 at 1:00 AM | Base Camp Trading (Ad)NewcelX Ltd. treibt IND-vorbereitende Aktivitäten für NCEL-101 nach erfolgreichem Pre-IND-Treffen mit der FDA voranSeptember 30, 2026 | de.marketscreener.comDNewCelX Management to Attend Breakthrough T1D Congress in Philadelphia, Advancing Its Mission to Develop a Cure for Type 1 DiabetesSeptember 28, 2026 | globenewswire.comDer aktuelle Kurs der NewcelX AG Aktie beträgt 3,380.August 27, 2026 | de.investing.comSee More NLS Pharmaceutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like NLS Pharmaceutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on NLS Pharmaceutics and other key companies, straight to your email. Email Address About NLS PharmaceuticsNLS Pharmaceutics (NASDAQ:NCEL) was a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its drug-development programs included Quilience, an extended-release formulation of mazindol investigated for narcolepsy-related symptoms. Following a business combination with Israeli biotechnology company Kadimastem, NLS Pharmaceutics changed its name to NewcelX Ltd. and began trading on Nasdaq under the symbol NCEL. The combined company’s programs include Kadimastem’s cell-therapy candidates AstroRx, developed for amyotrophic lateral sclerosis, and IsletRx, being developed for diabetes.View NLS Pharmaceutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its YearThe Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to WatchTyson Foods' Earnings Beat Hides a Warning for Consumer Staples Dividend InvestorsMongoDB's Biggest Advantage May Be GitLab's Biggest WeaknessMicrosoft's Outage Barely Moved Its Stock, But a Bigger Risk May Be BuildingTyson Foods' 10% Surge Puts a Breakout in Sight, But Wall Street Remains CautiousOndas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog? Upcoming Earnings Lowe's Companies (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026)PDD (11/19/2026)Ross Stores (11/19/2026)Walmart (11/19/2026)Intuit (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.